ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial

Xu, Jianming*; Jiang, Haiping; Pan, Yueyin; Gu, Kangsheng; Cang, Shundong; Han, Lei; Shu, Yongqian; Li, Jiayi; Zhao, Junhui; Pan, Hongming; Luo, Suxia; Qin, Yanru; Guo, Qunyi; Bai, Yuxian; Ling, Yang; Yang, Jianwei; Yan, Zhilong; Yang, Lei; Tang, Yong; He, Yifu; Zhang, Liangming; Liang, Xinjun; Niu, Zuoxing; Zhang, Jingdong; Mao, Yong; Guo, Yingmei; Peng, Bo; Li, Ziran; Liu, Ying; Wang, Yan; Zhou, Hui安徽医科大学; 江南大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 厦门大学; 1; 5
JAMA2023-12-5DOI: 10.1001/jama.2023.19918
8阅读
引用收藏
分享

摘要

<bold>Importance</bold> Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherapy, has demonstrated promising efficacy.<bold>Objective</bold> To compare overall survival of patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancers who were treated with sintilimab with chemotherapy vs placebo with chemotherapy. Also compared were a subset of patients with a PD ligand 1 (PD-L1) combined positive score (CPS) of 5 or more (range, 1-100).<bold>Design, Setting, and Participants</bold> Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 62 hospitals in China that enrolled 650 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma between January 3, 2019, and August 5, 2020. Final follow-up occurred on June 20, 2021.<bold>Interventions</bold> Patients were randomized 1:1 to either sintilimab (n = 327) or placebo (n = 323) combined with capecitabine and oxaliplatin (the XELOX regimen) every 3 weeks for a maximum of 6 cycles. Maintenance therapy with sintilimab or placebo plus capecitabine continued for up to 2 years.<bold>Main Outcomes and Measures</bold> The primary end point was overall survival time from randomization.<bold>Results</bold> Of the 650 patients (mean age, 59 years; 483 [74.3%] men), 327 were randomized to sintilimab plus chemotherapy and 323 to placebo plus chemotherapy. Among the randomized patients, 397 (61.1%) had tumors with a PD-L1 CPS of 5 or more; 563 (86.6%) discontinued study treatment and 388 (59.7%) died; 1 patient (<0.1%) was lost to follow-up. Among all randomized patients, sintilimab improved overall survival compared with placebo (median, 15.2 vs 12.3 months; stratified hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]; P = .009). Among patients with a CPS of 5 or more, sintilimab improved overall survival compared with placebo (median, 18.4 vs 12.9 months; HR, 0.66 [95% CI, 0.50-0.86]; P = .002). The most common grade 3 or higher treatment-related adverse events were decreased platelet count (sintilimab, 24.7% vs placebo, 21.3%), decreased neutrophil count (sintilimab, 20.1% vs placebo, 18.8%), and anemia (sintilimab, 12.5% vs placebo, 8.8%).<bold>Conclusions and Relevance</bold> Among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy, sintilimab significantly improved overall survival for all patients and for patients with a CPS of 5 or more compared with placebo.

学科与关键词

关键词
1ST-LINE THERAPYOPEN-LABELPHASE-IIICISPLATINCAPECITABINE
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
JAMA
发表日期
2023-12-05
卷期
第 330 卷, 第 21 期
页码
2064-2074
DOI
10.1001/jama.2023.19918
语言
ENGLISH
成果收录
SCIE
资助标注
Innovent Biologics, Inc

作者

  • X

    Xu, Jianming (通讯) (第一作者)

    5 · chinese peoples liberat army gen hosp

  • J

    Jiang, Haiping

    1 · zhejiang univ

查看全部 31 位作者收起作者
  • P

    Pan, Yueyin

    anhui prov hosp

  • G

    Gu, Kangsheng

    1 · anhui med univ

  • C

    Cang, Shundong

    henan prov peoples hosp

  • H

    Han, Lei

    jining med univ

  • S

    Shu, Yongqian

  • L

    Li, Jiayi

    1 · xiamen univ

  • Z

    Zhao, Junhui

    qinghai univ

  • P

    Pan, Hongming

    zhejiang univ

  • L

    Luo, Suxia

  • Q

    Qin, Yanru

    1 · zhengzhou univ

  • G

    Guo, Qunyi

  • B

    Bai, Yuxian

    harbin med univ

  • L

    Ling, Yang

  • Y

    Yang, Jianwei

    fujian prov canc hosp

  • Y

    Yan, Zhilong

  • Y

    Yang, Lei

  • T

    Tang, Yong

    xinjiang med univ

  • H

    He, Yifu

  • Z

    Zhang, Liangming

    yantai yuhuangding hosp

  • L

    Liang, Xinjun

    hubei canc hosp

  • N

    Niu, Zuoxing

  • Z

    Zhang, Jingdong

    liaoning canc hosp

  • M

    Mao, Yong

    jiangnan univ

  • G

    Guo, Yingmei

  • P

    Peng, Bo

  • L

    Li, Ziran

  • L

    Liu, Ying

  • W

    Wang, Yan

  • Z

    Zhou, Hui

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417